

# UCSF

## UC San Francisco Previously Published Works

### Title

PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters

### Permalink

<https://escholarship.org/uc/item/96t7w90t>

### Journal

Clinical Pharmacology & Therapeutics, 103(3)

### ISSN

0009-9236

### Authors

Hsueh, C-H  
Hsu, V  
Zhao, P  
[et al.](#)

### Publication Date

2018-03-01

### DOI

10.1002/cpt.750

Peer reviewed

# PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters

C-H Hsueh<sup>1,2,3</sup>, V Hsu<sup>2</sup>, P Zhao<sup>2</sup>, L Zhang<sup>2</sup>, KM Giacomini<sup>1</sup> and S-M Huang<sup>2</sup>

Altered pharmacokinetics (PK) in subjects with chronic kidney disease (CKD) may lead to dosing adjustment of certain drugs in subjects with CKD. It can be valuable to quantitatively predict PK in CKD for the management of drug dosing in these subjects. We developed physiologically based pharmacokinetic (PBPK) models of seven renally eliminated drugs: adefovir, avibactam, entecavir, famotidine, ganciclovir, oseltamivir carboxylate, and sitagliptin. These drugs are all substrates of renal organic anion transporters (OATs). Drug models verified using PK data from healthy subjects (HS) were coupled with physiological models representing CKD that incorporated prior knowledge of effects of CKD on hepatic and renal elimination. The models reasonably described clinically observed PK changes in subjects with CKD (compared to subjects with normal renal function), with predicted AUC changes within 50% of the observed changes. PBPK models can be used to prospectively predict PK of renally eliminated OAT substrates in subjects with CKD.

## Study Highlights

### WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?

✔ PBPK modeling is a useful tool but could be challenging when predicting drug pharmacokinetics (PK) in a specific population such as the CKD population.

### WHAT QUESTION DID THIS STUDY ADDRESS?

✔ To determine if PBPK models informed by current knowledge can be used to predict PK in CKD subjects for drugs that are excreted renally by organic anion transporters (OATs).

### WHAT THIS STUDY ADDS TO OUR KNOWLEDGE

✔ Predictive performance appears to be established for predicting PK of renally cleared OAT substrates in CKD subjects by PBPK models.

### HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE

✔ For a renally cleared OAT substrate, considerations proposed in this work can be taken to quantitatively predict its PK and to support dosing recommendations in CKD.

The kidneys play a critical role in drug disposition. Of the top prescribed drugs in the US, more than 90% of the renally eliminated drugs undergo (net) tubular secretion, which may significantly contribute to the renal clearance ( $CL_r$ ).<sup>1</sup> As a substantial portion of people in the US suffer from chronic kidney diseases (CKD) and many of them require multiple medications, dosing drugs properly based on the altered pharmacokinetic (PK) in these subjects is important.<sup>2</sup> In CKD subjects, reduction in both glomerular filtration and tubular secretion can lead to a significant decrease in  $CL_r$  for renally eliminated drugs. Consequently, for those subjects doses may need to be adjusted.


An effective dosage adjustment of a therapeutic drug in CKD subjects requires an understanding of its clearance mechanism and quantitative effects of CKD on various pathways relevant to the drug's disposition. For renally cleared drugs, changes in glomerular filtration can be quantified in CKD. However, there seems to be a lack of consensus on the effect of CKD on tubular secretion. Bricker *et al.* introduced the intact nephron hypothesis

(INH), which proposed that damaged nephrons stop working completely, whereas undamaged nephrons are functionally normal in subjects with reduced kidney function.<sup>3,4</sup> The INH, which predicts that glomerular filtration and tubular secretion decline in parallel, is consistent with  $CL_r$  for some drugs in subjects with various degrees of CKD, e.g., memantine.<sup>5</sup> Our recent study of drugs that are transported by organic anion transporters (OATs) might challenge this hypothesis.<sup>6</sup> We showed that reductions of glomerular filtration rate (GFR) and the secretory clearance ( $CL_{sec}$ , via tubular secretion) for these drugs were disproportional, particularly in severe CKD subjects. The reduction in  $CL_{sec}$  appears to be greater than that of GFR. We also showed that the activity of OATs can be inhibited by uremic solutes at clinically relevant concentrations. These solutes are metabolites synthesized in the body, and can accumulate to very high concentrations in advanced CKD subjects.<sup>6</sup> This may explain the disproportional deteriorations of glomerular filtration and tubular secretion observed in subjects with CKD for these OAT substrates. The

<sup>1</sup>Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA; <sup>2</sup>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA; <sup>3</sup>Oak Ridge Institute for Science and Education (ORISE) Fellow, Oak Ridge, Tennessee, USA. Correspondence: P Zhao (Ping.zhao@gatesfoundation.org)

Received 10 March 2017; accepted 16 May 2017; advance online publication 00 Month 2017. doi:10.1002/cpt.750

## CKD Stage/Progression



**Figure 1** Key hypotheses in this study. INH, intact nephron hypothesis;  $CL_{sec}$ , secretory clearance;  $CL_{OATs}$ , intrinsic clearance mediated by OATs. [Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)]

inhibition of other renal transporters by uremic solutes remains to be elucidated. In addition to renal elimination pathways, CKD might affect hepatic drug metabolism.<sup>6,7</sup>

The process-specific changes in CKD make prospective prediction of drug PK a challenging task. Because CKD involves a complex/dynamic alteration of physiology, the physiologically based pharmacokinetic (PBPK) model, which incorporates both drug-specific parameters and physiological parameters, can be used to predict the effect of CKD on drug exposure.<sup>8</sup> In this study, we developed PBPK models for seven renally cleared drugs that are OAT substrates. The need to consider inhibition of OAT activities in addition to INH was evaluated and confirmed through our analysis. These findings allowed us to propose a model-based framework for prospectively predicting PK profiles of renally cleared OAT substrates in CKD subjects. The key hypotheses are depicted in **Figure 1**.

## RESULTS

## PBPK models in healthy subjects (HS)

The drug-specific parameters of the seven drugs are shown in **Table 1**. All drugs are predominantly excreted by the kidney (fraction excreted unchanged ( $f_e$ ) >0.65) and are known substrates of OATs. Of note, the tubular secretion of these drugs accounts for between 27% for avibactam (AVI) and 78% for entecavir (ETV) of the corresponding  $CL_r$ , suggesting the importance of the renal tubular secretion in their elimination, presumably by OATs. We assumed OATs contribute to most of the  $CL_{sec}$  for these drugs but the potential involvement of other transporters could not be ruled out. The models were verified with datasets that were not used during model development. Examples of the simulated data vs. observed data in the verification dataset can be found in **Supplementary Figure 1** and **Supplementary Table 1**. These base models also described well the PK (area under the curve (AUC) and  $CL_r$ ) of HS in the CKD trials (**Supplementary Table 2**).

## Prediction of the effect of CKD on drug PK using PBPK modeling

Drug PK in CKD populations was prospectively predicted using models developed and verified in HS in virtual populations representing specific CKD groups (**Figure 2, Supplementary Table 2**). The models appear to reasonably describe observed changes in AUC and  $CL_r$  in CKDs, as measured by AUC ratio (AUCR, CKD/HS) and  $CL_r$  ratio ( $CL_{r,R}$ , CKD/HS) across seven drugs for various CKD stages. All predicted AUCRs (**Figure 2, middle panel**) and most of the predicted  $CL_{r,R}$ s were within 1.5-fold of the observed data (**Figure 2, dashed lines**). Predicted  $CL_{r,R}$ s for adefovir (ADV) was not within the 1.5-fold of the observed data in severe CKD (0.66 of observed value). In addition, 14 and 15 of the 21 predicted AUCR (67%) and  $CL_{r,R}$  (71%), respectively, were within a more stringent 1.25-fold of the observed data (**Figure 2, dotted lines**).

## DISCUSSION

We demonstrated that PBPK models considering effects of CKD on tubular secretion (assuming INH), hepatic elimination, and inhibition of OATs by uremic solutes reasonably described PK of seven renally cleared OAT substrates in patients of different CKD stages.<sup>9–13</sup>

INH reasonably predicted  $CL_{r,R}$  in the early stages of CKD

Anatomic evidence shows that the renal injury in CKD could occur in glomeruli but not in renal tubules (aglomerular tubules) and vice versa (atubular glomerulus). The INH hypothesizes that, despite this anatomical observation showing heterogeneous sources of renal damage, once a nephron is injured, it does not belong to the functional nephron population.<sup>3,4</sup> The persisting nephrons will compensate for the nephron loss. In a way, the nephrons remain functionally homogenous. This has been supported by animal studies.<sup>3</sup> By physically injuring a single kidney and surgically separating the urinary bladder into two, researchers were able to compare diseased and healthy kidney in the same animal.

**Table 1 Drug-specific parameters in PBPK models**

	ADV	AVI	ETV	FAM	GCV	OC <sup>e</sup>	SITA
<b>Physicochemical Properties</b>							
Molecular weight (g/mol)	273	265	277	338	255	284	407
logP <sup>a</sup>	-2.8	-1.8	-1.4	-0.98 <sup>31</sup>	1.66	-2.4	1.95
Compound type	amph	acid	amph	base	amph	amph	base
pKa <sup>a</sup>	2/6.8	0	2.77/8	6.8 <sup>31</sup>	2.2/9.4	3.6/8.2	8.8
B/P	0.55 <sup>28</sup>	0.76 <sup>40</sup>	1 <sup>41</sup>	0.9 <sup>32</sup>	1 <sup>36</sup>	0.6	1 <sup>49</sup>
fu <sup>a</sup>	0.96	0.93 <sup>39</sup>	0.87 <sup>41</sup>	0.83	0.98 <sup>36</sup>	0.97	0.65
<b>Absorption</b>							
Model	ADAM	N/A	1 <sup>st</sup> order	N/A	1 <sup>st</sup> order	1 <sup>st</sup> order	1 <sup>st</sup> order
fa		N/A	0.94 <sup>41</sup>	N/A	0.61 <sup>35</sup>	0.8	1 <sup>30</sup>
Ka (1/h)		N/A	1.25 <sup>41</sup>	N/A	2.56 <sup>36</sup>	0.11	0.33 <sup>30</sup>
Lag time (h)		N/A	0 <sup>41</sup>	N/A	0.31 <sup>36</sup>	1.38	0 <sup>30</sup>
Pe <sub>ff, man</sub> (10 <sup>-4</sup> cm/s)	0.25 <sup>a27</sup>	N/A	0.91 <sup>f</sup>	N/A	5.38 <sup>f</sup>	9.56 <sup>f</sup>	0.24 <sup>f</sup>
<b>Distribution</b>							
V <sub>ss</sub> (L/kg) <sup>b</sup>	0.4 <sup>26</sup>	0.2 <sup>37</sup>	0.9 <sup>41</sup>	1.2 <sup>34</sup>	0.8 <sup>36</sup>	0.4 <sup>29</sup>	2.3 <sup>49</sup>
K <sub>p</sub> scalar <sup>p</sup>	1.3	0.7	2.5	2.5	0.5	0.8	0.9
<b>Elimination</b>							
CL <sub>r</sub> (L/h)	15.6 <sup>26</sup>	9.23 <sup>37</sup>	23.1 <sup>42</sup>	18.6 <sup>33</sup>	12.2 <sup>36</sup>	19	17.4 <sup>30</sup>
CL <sub>nr</sub> (L/h)	1.3 <sup>26</sup>	0.9 <sup>37</sup>	13.3 <sup>42</sup>	9.1 <sup>33</sup>	0 <sup>36</sup>	0	7.6 <sup>30</sup>
%TS of CL <sub>r</sub>	56	27	78	68	42	63	73
fe (%)	83.7 <sup>28</sup>	92 <sup>37</sup>	70 <sup>h42</sup>	67 <sup>33</sup>	100 <sup>36</sup>	100 <sup>39</sup>	65 <sup>30</sup>
<b>Transport</b>							
CL <sub>int,T</sub> by OATs <sup>c</sup> (μl/min/10 <sup>6</sup> cells)	14.4 <sup>26</sup>	5.3 <sup>37</sup>	26.7 <sup>41</sup>	24.5 <sup>33</sup>	11.3 <sup>36</sup>	19 <sup>29</sup>	22.8 <sup>30</sup>
CL <sub>int,T</sub> by Eff <sup>d</sup> (μl/min/10 <sup>6</sup> cells)	1	1	1	1	1	1	1
CL <sub>PD</sub> <sup>e</sup> (ml/min/10 <sup>6</sup> proximal tubular cells)	3.28	0	0	8.45	0	1.86	0


ADV, adefovir; amph, ampholyte; AVI, avibactam; B/P, blood to plasma ratio; CL<sub>int,T</sub> by Eff, in vitro efflux transporter-mediated clearance for the apical transporter; CL<sub>int,T</sub> by OATs, in vitro OATs-mediated clearance; CL<sub>nr</sub>, non-renal clearance; CL<sub>r</sub>, renal clearance; ETV, entecavir; fa, fraction absorbed; FAM, famotidine; fe, fraction excreted unchanged; fu, Fraction unbound in plasma; GCV, ganciclovir; Ka, First order absorption rate constant; OC, oseltamivir carboxylate; %TS of CL<sub>r</sub>, percentage of tubular secretion contributed to renal clearance, calculated as (CL<sub>r</sub> - fu\*GFR) / CL<sub>r</sub>, where CL<sub>r</sub> is the renal clearance, fu is the fraction unbound and GFR is the glomerular filtration rate; Pe<sub>ff, man</sub>, effective permeability in man; SITA, sitagliptin; V<sub>ss</sub>, volume of distribution at steady state.

<sup>a</sup>Unless otherwise specified, values were collected from online resources such as drugbank (<https://www.drugbank.ca/>) and pubchem (<https://pubchem.ncbi.nlm.nih.gov/>); <sup>b</sup>predicted<sup>44,45</sup> and K<sub>p</sub> scalar was adjusted to match clinical observations; <sup>c</sup>fitted from plasma concentration-time profiles by parameter estimation while keeping relative activity factor/relative expression factor (RAF/REF) = 1 in HS; <sup>d</sup>CL<sub>int,T</sub> by Eff was unidentifiable and was obtained by sensitivity analysis to match drug accumulation in the urine (fe) as reported by Hsu et al.<sup>14</sup> The default value of 1 was then used for all drugs since it was sufficient to reasonably describe observed CL<sub>r</sub> and fe; <sup>e</sup>passive diffusion clearance, estimated from the passive permeability measured in HEK293 cells using metformin as the standard<sup>47</sup>; <sup>f</sup>predicted by software's mechanistic permeability model; <sup>g</sup>modified from Hsu et al.<sup>14</sup>; <sup>h</sup>percentage of dose recovered in urine unchanged ml/min/10<sup>6</sup> cells to tubule.

The ratio of effective renal plasma flow over GFR and the ratio of maximum tubular excretion of para-aminohippuric acid (PAH) over GFR were comparable for diseased and healthy kidneys. This endorsed the concept of the INH. In our models, we reduce CL<sub>sec</sub> in accordance with GFR by reducing the number of proximal tubular cells per gram kidney (PTCPGK). This is based on the pilot study by Hsu *et al.*<sup>14</sup> Adjustment of this number represents INH better, as it describes the loss of tubular cells. PBPK models with this adjustment appear to describe observed changes in CL<sub>r</sub> in mild and/or moderate CKD.

### Insufficiency of the INH to explain PK change in severe CKD

Interestingly, the INH alone underpredicted the reduction in CL<sub>r</sub> (higher predicted CL<sub>r,R</sub>) in severe CKD in our PBPK models (**Supplemental Figure 2**). In the animal model described above,<sup>15,16</sup> uremic solutes would not accumulate, since at least one kidney remains intact. In contrast, in an animal model of acute kidney injury induced by chemicals, both kidneys would be damaged and uremic solutes are expected to accumulate. Notably, PAH clearance showed a greater reduction than GFR in the acute kidney injury, consistent with a suppression in tubular




**Figure 2** Predicted AUCR and CL<sub>r</sub>R vs. observed values. The black solid line is the unity line. Dashed and dotted lines denote 0.67–1.5x criterion and 0.8–1.25x criterion, respectively. ADV, adefovir; AUCR, ratios of area under the curves (CKD/HS); AVI, avibactam; CL<sub>r</sub>R, ratios of renal clearances (CKD/HS); ETV, entecavir; FAM, famotidine; GCV, ganciclovir; OC, oseltamivir carboxylate; SITA, sitagliptin.

activity by the solutes.<sup>15,16</sup> PAH is a well-known substrate of OATs. In the analysis by Hsueh *et al.*, drugs that were excreted by OATs showed a greater reduction of CL<sub>sec</sub> compared to GFR, particularly in severe CKD.<sup>6</sup> The study also demonstrated that several uremic solutes were clinically relevant inhibitors of OATs. Overall, the evidence suggests that on top of the INH, reduction of intrinsic clearance mediated by OATs (CL<sub>OATs</sub>) is observed clinically, and is presumably a result of an accumulation of uremic solutes. Indeed, an additional reduction in the CL<sub>OATs</sub> is needed to restore the observed clinically CL<sub>r</sub>R in our models. Overall, the simulations support our proposal of incorporating inhibition of CL<sub>OATs</sub> in severe CKD (**Figure 3**).

### Degree of the CL<sub>OATs</sub> reduction in CKD

It might not be necessary to adjust CL<sub>OATs</sub> for mild and moderate CKD (**Supplementary Figure 2**, right panel). The INH appears sufficient to capture the CL<sub>r</sub>R observed clinically, even

though statistical analyses favor a 0–10% reduction in CL<sub>OATs</sub> in moderate CKD (**Supplementary Table 3**). In contrast, it is clear that INH alone is not sufficient to describe the CL<sub>r</sub>R in severe CKD. A reduction in CL<sub>OATs</sub> is necessary. The best values to reduce CL<sub>OATs</sub> in severe CKD fall within 40–55%. Based on the analysis from 18 CKD trials, the median value of CL<sub>OATs</sub> reductions is around 27% and 59% for moderate and severe CKD, respectively (values used in prospective predictions in **Figure 2**).<sup>6</sup> The values are different from the best descriptors here (27% vs. 0–10% for moderate CKD and 59% vs. 40–55% for severe CKD). The concentrations of uremic solutes are susceptible to the impacts of environment, GFR, food, etc. If uremic solutes are indeed the key factor that leads to the reduction in the CL<sub>OATs</sub>, differential accumulations of uremic solutes among CKD trials might potentially explain the difference in the best descriptors. In addition, we assumed that OATs are responsible for CL<sub>sec</sub> of all test drugs. A significant contribution by other transporters to



**Figure 3** A procedure to use PBPK modeling to predict drug PK in CKD. CKD, chronic kidney disease; CL<sub>r</sub>, renal clearance; CL<sub>sec</sub>, secretory clearance (CL<sub>r</sub> – fu\*GFR); fe, fraction excreted unchanged; fu, fraction unbound; GFR, glomerular filtration rate; HS, healthy subjects; INH, intact nephron hypothesis; OAT, organic anion transporters. <sup>a</sup>Suggested mean (range) values are 31% (18–45%) and 36% (20–52%) for moderate and severe CKD, respectively, as reported by Sayama *et al.*<sup>18</sup> <sup>b</sup>Suggested mean (range) value of 45% (35–55%) for severe CKD, based on the sensitivity analysis (**Supplementary Table 3**). <sup>c</sup>Although ~5% reduced CL<sub>OATs</sub> best described the clinical observations, there was little improvement in model performance. Therefore, it might not be necessary to adjust CL<sub>OATs</sub> in moderate CKD.

$CL_{sec}$  may affect prediction and calculation of best descriptors. Nevertheless, both support the need to reduce  $CL_{OATs}$  in CKD, particularly in severe CKD. The assumption that OATs are responsible for all  $CL_{sec}$  also ensures the conservativeness of prospective prediction of an investigational OAT substrate in severe CKD.

The understanding of uremic solutes in CKD is increasing but still requires much work. For example, the reported concentrations are usually from subjects with end stage renal disease (ESRD) during the off-dialysis period. Concentrations of many solutes in other stages of CKD remain unavailable. Furthermore, it is unclear if there are other unidentified solutes that potentially inhibit OATs. As such, although adjusting the  $CL_{OATs}$  based on the inhibitory potencies ( $[I]/IC_{50}$ ) of uremic solutes is more mechanistic, it is not deployed here.

#### Degree of the nonrenal clearance ( $CL_{nr}$ ) reduction in CKD

Increasing data suggest that CKD impairs  $CL_{nr}$  as well as  $CL_r$ .<sup>9,10,13,17</sup> Thus, it is now recommended that changes in  $CL_{nr}$  be included in the development of PBPK models to predict PK of drugs in CKD.<sup>18,19</sup> Our data partially confirmed these findings. The confirmation of  $CL_r$  followed by AUCR allowed us to examine the need of  $CL_{nr}$  reduction. Even when the predicted  $CL_r$  matched the observed data, the AUCR could still be underpredicted unless a reduction in the  $CL_{nr}$  was applied. This is most obvious for severe CKD and for drugs with relatively high  $CL_{nr}$ , such as ETV, sitagliptin (SITA), and famotidine (FAM) (**Supplementary Figure 2**, middle panel, and **Supplementary Figure 3**). Intuitively for adefovir (ADV), AVI, ganciclovir (GCV), and oseltamivir carboxylate (OC), whose  $CL_{nr}$  contributes little to the total CL ( $f_e > 0.8$ ), the effect of reduced  $CL_{nr}$  on the predicted AUCR is negligible. Different nonrenal elimination pathways are responsible for the seven compounds studied here, and contributed to the total CL from 0% (OC) to 37% (ETV). The best scaling factor for the  $CL_{nr}$  in CKD was not evaluated in our study because of its relatively insignificant contribution compared to the renal pathway. Due to the lack of knowledge of the quantitative impact of CKD on different nonrenal elimination pathways, the same scaling factor was considered to account for the reduction of  $CL_{nr}$  in CKD. That was 31% and 36% reduction in the  $CL_{nr}$  for moderate and severe CKD, respectively, which represented the average values from the ranges reported by Sayama *et al.*<sup>19</sup> It appears that the use of these factors worked for drugs predominately renally excreted. However, for those drugs whose  $CL_{nr}$  contribute significantly to the total CL, it should be evaluated carefully.

#### Other variables that might be considered

In this study, we assumed that CKD does not affect oral absorption. However, increased bioavailability in the subjects with CKD has been reported.<sup>13</sup> This could be due to the reduced  $CL_{nr}$  (reduced first pass effect) or reduced intestinal P-glycoprotein (P-gp).<sup>20</sup> ETV and SITA are substrates of P-gp. Since the fraction absorbed ( $F_a$ ) for these two drugs are relatively high (0.94 for ETV and 1 for SITA), the effect of CKD on intestinal P-gp (e.g., a reduction of its activity) may be negligible.

Active uptake, if any, into the liver or other elimination organs except for the kidneys was not considered in our model either. The expressions/activities of those transporters might be subject to change in CKD. Although the procedure of reducing  $CL_{nr}$  could in part account for the effect of transporters in other organs, the incorporation of other transporter information may improve model performance.

In this study, fraction unbound in plasma ( $f_u$ ) was assumed to be constant regardless of the degree of CKD. It is appropriate here, because six out of the seven drugs had  $f_u$  values greater than 0.8. SITA is the most protein-bound drug in this study ( $f_u = 0.65$ ) and was reported to show no change of  $f_u$  in subjects with severe CKD.<sup>21</sup> However, for those highly protein-bound drugs, significant changes in protein binding by CKD are expected. It might be necessary to consider altered  $f_u$ .

As OATs are highly abundant in the kidney and interact with structurally diverse organic anions, our assumption that the seven drugs studied here were eliminated via OATs may be valid. When coadministered with probenecid,  $CL_{sec}$  of FAM reduced by ~89%,<sup>22</sup> suggesting little involvement of other transporters. The contribution of transporters other than OATs cannot be excluded. Further studies are needed to understand if an additional reduction is required for  $CL_r$  mediated by other transporters, such as OCT2.<sup>23</sup>

It is also unclear whether our approach can be generalized to drugs with a smaller contribution of secretion, whose renal elimination is sensitive to urine pH and flow, and which undergo significant reabsorption.

Renal blood flow reduces in CKD. The effect of renal blood flow change on  $CL_r$  of test drugs remains unknown. However, there is a report showing that the ratio of renal blood flow and kidney size remains consistent in CKD.<sup>24</sup> The software considers changes in kidney size by CKD.

#### Prediction of drug disposition in subjects with CKD

Based on our analyses and current understanding of the impact of CKD on drug elimination, we summarize the use of PBPK models to predict the PK of renally cleared drugs ( $f_e > 0.65$ ) secreted by renal OATs in CKD populations (**Figure 3**). The procedure begins with development and verification of a drug PK model in HS. For mild CKD, the use of INH, which assumes proportional reduction of GFR and  $CL_{sec}$ , appears sufficient. For moderate CKD, reduction in  $CL_{nr}$  should be considered besides the INH. In addition to these two adjustments (INH and reduced  $CL_{nr}$ ), a further reduction in  $CL_{OATs}$  is required for predicting PK in severe CKD.

#### CONCLUSION

Application of PBPK models has been employed in drug development to evaluate drug PK, and to support dosing recommendations.<sup>8</sup> Clinical PK studies in CKD are often needed in the early phase of drug development and the design and conduct of such studies can be challenging. Here we have demonstrated the reasonable performance of PBPK models to predict the PK of renally cleared OAT substrates in CKD. Our analysis indicates that for mild or moderate CKD the INH is sufficient to predict

reductions in  $CL_r$ ; however, for severe CKD an adjustment for reduced  $CL_{sec}$  needs to be made, potentially as a result of the accumulation of uremic solutes that inhibit OATs. Although there are limitations and further verification/refinement is needed, considerations proposed in this work can be taken to quantitatively predict PK in CKD and to support dosing recommendations, specifically for a renally cleared drug that is an OAT substrate.

## METHODS

**Figure 1** summarizes the key hypotheses: 1) A nephron is the smallest functional unit of the kidney and is composed of the glomerulus and renal tubules. 2) In the early stages of CKD, GFR reduces in subjects with CKD with a proportional reduction of the tubular secretion, as suggested by INH. 3) OATs are critical to the elimination of many drugs excreted by tubular secretion. 4) As the renal function further declines, circulating uremic solutes accumulate to concentrations that can inhibit OATs in subjects with CKD, further reducing  $CL_{OATs}$  in the functional nephrons.<sup>6</sup> 5) In addition to  $CL_r$ ,  $CL_{nr}$  reduces in subjects with CKD.<sup>18,19</sup>

### Drug selection and development of drug PBPK models in HS

Seven drugs with  $f_u$  from 0.65 to 1 were selected. The PBPK models were constructed using a population-based PBPK software SimCYP (a Certara Company, Sheffield, UK, v. 15.1).<sup>25</sup> Drug-dependent parameters were collected from the literature and are shown in **Table 1**.<sup>14,26–43</sup> The PBPK models in HS were developed by incorporating physicochemical properties, *in vitro* data on drug disposition, and observed PK in HS. Full PBPK distribution models were selected for all drugs to enable the use of the mechanistic kidney model (Mech KiM) (see below).<sup>44</sup> Tissue distributions were predicted by Rodgers *et al.*<sup>45,46</sup> and the “ $K_p$  Scalar” was adjusted to match the observed volume of distribution at steady state ( $V_{ss}$ ).

$CL_{nr}$  was back-calculated from systemic clearance ( $CL_{sys}$ ) and  $CL_r$ , and was assigned to an undefined hepatic clearance. Values of  $CL_{sys}$  after intravenous (i.v.) drug administration were available for all drugs except for ETV. For ETV, an  $f_a$  of 0.94 was obtained from a human mass balance study and fraction escaping intestinal metabolism of 1 was assumed because the drug has not been shown to be metabolized by metabolizing enzymes that are significantly expressed in enterocytes. These assumptions allowed the use of retrograde analysis to derive  $CL_{nr}$  from apparent clearance after oral drug administration.

The  $CL_r$  was described by Mech KiM.<sup>44</sup> Tubular secretion was parameterized by a net tubular uptake transporter to represent the OAT-mediated process as described previously.<sup>14</sup> Passive permeability of the renal tubular cell was included in the models of ADV, FAM, and OC (passive diffusion clearance, **Table 1**), as *in vitro* data were available. This was calculated from the measured passive permeability in HEK293 cells using metformin as the standard.<sup>47</sup> Passive diffusion clearance was assumed zero for AVI, ETV, GCV, and SITA due to the lack of passive permeability information. Then  $CL_{OATs}$  were obtained using the parameter estimation function against plasma concentration–time profiles after i.v. administration (**Table 1**), except for ETV (see below).

Parameters describing oral absorption were acquired after the estimation of  $CL_{OATs}$ . Fraction absorbed ( $f_a$ ) was estimated from the absolute bioavailability studies (GCV, OC, and SITA) or a mass balance study (ETV). First-order absorption rate constant ( $k_a$ ) and lag time (Tlag) were optimized to match the observed concentration–time profiles after oral administration using the parameter estimation function. As i.v. PK data were not available for ETV,  $CL_{OATs}$  was estimated along with  $k_a$  and Tlag. It is of note that adefovir dipivoxil, valganciclovir, and oseltamivir are the prodrugs of ADV, GCV, and OC, respectively. Approximation of the conversion of prodrugs to active metabolites was accomplished by using a first-order (for GCV and OC) or an Advanced Dissolution, Absorption, and Metabolism model (for ADV) oral absorption function

as the drug input, assuming that the administered prodrugs are instantaneously converted to the respective metabolites. The ADAM model was used for ADV because it best described its biotransformation process based on the plasma concentration–time profile of ADV after oral administration of adefovir dipivoxil. The doses were calculated based on the amounts of ADV, GCV, and OC in their prodrug forms. The values of coefficient of variation (CV) for all drug specific parameters were set to 30%.

### Physiological models in CKD populations

Once a drug model was generated and verified in HS, it was coupled with physiological models representing CKD populations (or virtual populations, described below) to simulate drug PK in CKD. Stages of CKD were generally defined as follows: HS (GFR  $\geq 90$  ml/min), mild CKD (60–89 ml/min), moderate CKD (30–59 ml/min), and severe CKD (15–29 ml/min). Software’s built-in “Sim-Healthy volunteer,” “Sim-RenalGFR\_30-60,” and “Sim-RenalGFR\_less30” virtual populations were used to further define the different physiological models. In addition to physiology changes already implemented in these virtual populations,<sup>18</sup> the following modifications were made before simulation of drug PK in CKD was conducted.

First, PTCPGK, a system parameter defined in the Mech KiM model,<sup>44</sup> was adjusted to represent INH by keeping a proportional reduction of GFR and tubular secretion for a given CKD group (**Supplementary Table 4**) according to the equation below:

$$\frac{CL_r,HS - f_u * GFR,HS}{GFR,HS} = \frac{CL_r,CKD - f_u * GFR,CKD}{GFR,CKD}$$

where  $f_u$  is the fraction unbound in plasma.

Next, the inhibitory effect of uremic solutes on the OATs and the effect of CKD on hepatic elimination were considered by applying the relative activity factor/relative expression factor (RAF/REF) values of 0.73 and 0.41 to  $CL_{int,OATs}$  in moderate and severe CKDs, respectively, for each test drug. These RAF/REF values represent a 27% and 59% reduction in secretory clearance in addition to INH, as derived from an analysis of 18 drugs by Hsueh *et al.* according to a static equation.<sup>6</sup> Of note, all drugs from this study were part of that analysis. Then a generic degree of reduction was applied to  $CL_{nr}$ . We applied an average reduction of 31% and 36% for moderate and severe CKD, respectively, as reported by Sayama *et al.*<sup>19</sup>

### Simulation design for CKD trials

Observed PK profiles and information on study design from CKD trials were collected from the literature.<sup>28,29,36,39,41,48,49</sup> In our simulations, age, GFR, sex, and dosing regimen were matched with the reported clinical trials, as summarized in **Supplementary Table 5**. Each simulation was conducted using 50 subjects (5 subjects  $\times$  10 trials). Modification was made to match the observed GFR for a specific study. This was accomplished by adjusting the plasma creatinine concentration in a given virtual population of the software to achieve the target GFR. For example, for mild CKD, the “Sim-Healthy volunteer” population was used as the template and an adjustment of creatinine concentration was made. As sex and age were not reported in CKD trials of ADV, a 50% female population was assumed. Due to the fact that CKD subjects are generally older, the age of subjects in the CKD group was also assumed to be older ( $30 \pm 7$  years for HV,  $38 \pm 6$  years for mild CKD, and  $50 \pm 8$  years for moderate and severe CKD).

### Model performance evaluation

The predicted AUCRs and  $CL_r$ s were compared to evaluate the model predictability. Less than 50% deviation from the observed ratio was arbitrarily regarded as a successful prediction. root mean square deviation (RMSD) and geometric mean fold error (GMFE) were used to compare the accuracy of model prediction. They are:

$$\text{RMSE} = \sqrt{\frac{1}{N} (\text{predicted ratio} - \text{observed ratio})^2}$$

$$\text{GMFE} = 10^{\sum \frac{|\log \frac{\text{predicted ratio}}{\text{observed ratio}}|}{N}}$$

Additional Supporting Information may be found in the online version of this article.

## ACKNOWLEDGMENTS

Funding for this article was made possible, in part, by the Food and Drug Administration (FDA) through the Medical Countermeasures Initiative. Dr. Chia-Hsiang Hsueh was supported in part by the appointments to the Research Participation Program at the Center for Drug Evaluation and Research, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the FDA.

## CONFLICT OF INTEREST/DISCLOSURE

The authors declare no conflict of interest. The views expressed in this article do not necessarily reflect the official policies nor endorsements of the Department of Health and Human Services.

## AUTHOR CONTRIBUTIONS

C-H.H., V.H., P.Z., L.Z., K.M.G., and S-M.H. wrote the article; C-H.H., P.Z., L.Z., K.M.G., and S-M.H. designed the research; C-H.H. and V.H. performed the research; C-H.H. and V.H. analyzed the data.

© 2017 American Society for Clinical Pharmacology and Therapeutics

- Morrissey, K.M., Stocker, S.L., Wittwer, M.B., Xu, L. & Giacomini, K.M. Renal transporters in drug development. *Annu. Rev. Pharmacol. Toxicol.* **53**, 503–529 (2013).
- United States Renal Data System. *2015 United States Renal Data System Annual Data Report: Epidemiology of Kidney Disease in the United States* (National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2015).
- Bricker, N.S., Morrin, P.A. & Kime, S.W., Jr. The pathologic physiology of chronic Bright's disease. An exposition of the "intact nephron hypothesis." *Am. J. Med.* **28**, 77–98 (1960).
- Bricker, N.S. On the meaning of the intact nephron hypothesis. *Am. J. Med.* **46**, 1–11 (1969).
- Verbeeck, R.K. & Musuamba, F.T. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. *Eur. J. Clin. Pharmacol.* **65**, 757–773 (2009).
- Hsueh, C.H. *et al.* Identification and quantitative assessment of uremic solutes as inhibitors of renal organic anion transporters, OAT1 and OAT3. *Mol. Pharm.* **13**, 3130–3140 (2016).
- Yeung, C.K., Shen, D.D., Thummel, K.E. & Himmelfarb, J. Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. *Kidney Int.* **85**, 522–528 (2014).
- Zhao, P. *et al.* Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. *Clin. Pharmacol. Ther.* **89**, 259–267 (2011).
- Zhang, Y. *et al.* Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. *Clin. Pharmacol. Ther.* **85**, 305–311 (2009).
- Zhang, L. *et al.* Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease. *J. Clin. Pharmacol.* **52**, 79S–90S (2012).
- Naud, J. *et al.* Effects of chronic renal failure on liver drug transporters. *Drug Metab. Dispos.* **36**, 124–128 (2008).
- Gai, Z. *et al.* Effect of chronic renal failure on the hepatic, intestinal, and renal expression of bile acid transporters. *Am. J. Physiol. Renal Physiol.* **306**, F130–137 (2014).
- Dreisbach, A.W. & Lertora, J.J. The effect of chronic renal failure on drug metabolism and transport. *Expert Opin. Drug Metab. Toxicol.* **4**, 1065–1074 (2008).
- Hsu, V. *et al.* Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations. *Clin. Pharmacokinet.* **53**, 283–293 (2014).
- Lin, J.H. & Lin, T.H. Renal handling of drugs in renal failure. I: differential effects of uranyl nitrate- and glycerol-induced acute renal failure on renal excretion of TEAB and PAH in rats. *J. Pharmacol. Exp. Ther.* **246**, 896–901 (1988).
- Gloff, C.A. & Benet, L.Z. Differential effects of the degree of renal damage on p-aminohippuric acid and inulin clearances in rats. *J. Pharmacokinet. Biopharm.* **17**, 169–177 (1989).
- Yoshida, K. *et al.* Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5. *Clin. Pharmacol. Ther.* **100**, 75–87 (2016).
- Rowland Yeo, K., Aarabi, M., Jamei, M. & Rostami-Hodjegan, A. Modeling and predicting drug pharmacokinetics in patients with renal impairment. *Expert Rev. Clin. Pharmacol.* **4**, 261–274 (2011).
- Sayama, H., Takubo, H., Komura, H., Kogayu, M. & Iwaki, M. Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients. *AAPS J.* **16**, 1018–1028 (2014).
- Naud, J. *et al.* Down-regulation of intestinal drug transporters in chronic renal failure in rats. *J. Pharmacol. Exp. Ther.* **320**, 978–985 (2007).
- Bergman, A.J. *et al.* Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. *Diabetes Care* **30**, 1862–1864 (2007).
- Oyama, V.I. & Berdahl, B.J. A model of Martian surface chemistry. *J. Mol. Evol.* **14**, 199–210 (1979).
- Cheung, K.W.K. *et al.* The effect of uremic solutes on the organic cation transporters, OCT2. *J Pharm Sci* (2017); e-pub ahead of print. doi:10.1016/j.xphs.2017.04.076.
- Khatir, D.S., Pedersen, M., Jespersen, B. & Buus, N.H. Evaluation of renal blood flow and oxygenation in CKD using magnetic resonance imaging. *Am. J. Kidney Dis.* **66**, 402–411 (2015).
- Jamei, M. *et al.* The Simcyp population-based ADME simulator. *Expert Opin. Drug Metab. Toxicol.* **5**, 211–223 (2009).
- Cundy, K.C. *et al.* Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. *Antimicrob. Agents Chemother.* **39**, 2401–2405 (1995).
- Sun, D.Q., Wang, H.S., Ni, M.Y., Wang, B.J. & Guo, R.C. Pharmacokinetics, safety and tolerance of single- and multiple-dose adefovir dipivoxil in healthy Chinese subjects. *Br. J. Clin. Pharmacol.* **63**, 15–23 (2007).
- US Food and Drug Administration. Hepsera (NDA 21-449) Clinical pharmacology and biopharmaceutics review(s). <[http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2002/21-449\\_Hepsera\\_biopharmr\\_P1.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-449_Hepsera_biopharmr_P1.pdf)> (FDA, 2002).
- He, G., Massarella, J. & Ward, P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. *Clin. Pharmacokinet.* **37**, 471–484 (1999).
- Bergman, A. *et al.* Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. *Biopharm. Drug Dispos.* **28**, 315–322 (2007).
- Degim, T., Zaimoglu, V., Akay, C. & Degim, Z. pH-Metric log K calculations of famotidine, naproxen, nizatidine, ranitidine and salicylic acid. *Farmaco* **56**, 659–663 (2001).
- Matsuda, Y. *et al.* Assessment of intestinal availability of various drugs in the oral absorption process using portal vein-cannulated rats. *Drug Metab. Dispos.* **40**, 2231–2238 (2012).
- Yeh, K.C. *et al.* Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies. *Biopharm. Drug Dispos.* **8**, 549–560 (1987).
- Gladziwa, U. *et al.* Pharmacokinetics and pharmacodynamics of famotidine in patients with reflux oesophagitis. *Eur. J. Clin. Pharmacol.* **44**, 357–360 (1993).
- Jung, D. & Dorr, A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. *J. Clin. Pharmacol.* **39**, 800–804 (1999).
- US Food and Drug Administration. VALCYTE (NDA 021304) Clinical pharmacology and biopharmaceutics review(s). <<http://www>



- accessdata.fda.gov/drugsatfda\_docs/nda/2001/21304.pdf\_Valcyte\_BioPharmr.pdf> (FDA, 2001).
37. Tarral, A. & Merdjan, H. Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers. *Clin. Ther.* **37**, 877–886 (2015).
  38. Tominaga, N. *et al.* Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers. *J. Infect. Chemother.* **21**, 551–558 (2015).
  39. US Food and Drug Administration. AVYCAZ (NDA 206494) Clinical pharmacology and biopharmaceutics review(s). <[http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2015/206494Orig1s000ClInPharmR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000ClInPharmR.pdf)> (FDA, 2015).
  40. Vishwanathan, K. *et al.* Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential. *Drug Metab. Dispos.* **42**, 932–942 (2014).
  41. US Food and Drug Administration. Baraclude (NDA 021298/021979) Clinical pharmacology and biopharmaceutics review(s). <[http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2005/21797\\_BARACLUDE\\_biopharmr.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_biopharmr.pdf)> (FDA, 2004).
  42. Yan, J.H. *et al.* Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. *J. Clin. Pharmacol.* **46**, 1250–1258 (2006).
  43. Zhao, F.J. *et al.* Salting-out homogeneous liquid-liquid extraction approach applied in sample pre-processing for the quantitative determination of entecavir in human plasma by LC-MS. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* **881–882**, 119–125 (2012).
  44. Neuhoff, S. *et al.* In *Transporters in Drug Development: Discovery, Optimization, Clinical Study and Regulation* (eds. Sugiyama, Y. & Steffansen, B.) 155–177 (Springer, New York, 2013).
  45. Rodgers, T., Leahy, D. & Rowland, M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. *J. Pharm. Sci.* **94**, 1259–1276 (2005).
  46. Rodgers, T. & Rowland, M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. *J. Pharm. Sci.* **95**, 1238–1257 (2006).
  47. Burt, H.J. *et al.* Metformin and cimetidine: physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions. *Eur. J. Pharm. Sci.* **88**, 70–82 (2016).
  48. Takabatake, T. *et al.* Pharmacokinetics of famotidine, a new H<sub>2</sub>-receptor antagonist, in relation to renal function. *Eur. J. Clin. Pharmacol.* **28**, 327–331 (1985).
  49. US Food and Drug Administration. JANUVIA (NDA 21995) Clinical pharmacology and biopharmaceutics review(s). <[http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2006/021995s000\\_ClinPharmR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf)> (FDA, 2006).